Rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPARγ) activator, is used as a treatment for type II diabetes and is a well-known in vitro inducer of browning in adipose mesenchymal stem cells (ADSCs), and it has recently been found to trigger the adipocyte-specific release of circulating miR-200a embedded in EVs. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.